Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients.